Pfizer pockets roughly £2.5B as it shaves off final stake in consumer health spinoff Haleon

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant.

After charting similar moves throughout 2024, Pfizer on Tuesday unveiled plans to sell roughly 662 million Haleon shares—representative of Pfizer’s entire remaining 7.3% stake in the company—to institutional investors and Haleon itself.